---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-26-004806"
form_type: "8-K"
ticker: "MDCX"
cik: "0001997296"
company_name: "Medicus Pharma Ltd."
filed_at: "2026-09-03T12:00:27+00:00"
generated_at: "2026-09-03T12:05:19.478078+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Medicus signs co-development license with Pfizer for CD228V ADC; $1B milestones

## Summary
- Exclusive worldwide license from Pfizer to develop/commercialize CD228V, an early-stage antibody-drug conjugate targeting CD228.
- Medicus pays $12.0M upfront plus $15.0M on first anniversary; Pfizer pays $2.0M development funding payment.
- Pfizer eligible for development, regulatory, and sales milestones exceeding $1.0B total, plus low double-digit tiered royalties.
- Medicus retains sole control over development, manufacture, regulatory approval, and commercialization; Pfizer holds option to fund pivotal trials.
- Deal effective September 2, 2026; filed as Exhibit 10.1 with redactions for confidential terms.

## SEC filing metadata
- accession: 0001062993-26-004806
- form_type: 8-K
- ticker: MDCX
- cik: 0001997296
- company_name: Medicus Pharma Ltd.
- filed_at: 2026-09-03T12:00:27+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1997296/000106299326004806/0001062993-26-004806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1997296/000106299326004806/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-26-004806
- JSON: https://secwatch.observer/filing/0001062993-26-004806.json
- Plain text: https://secwatch.observer/filing/0001062993-26-004806.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.